Richard Saitz, MD, MPH
Boston University School of Public Health
• Spectrum of unhealthy substance use
• Alcohol use and alcohol use disorder
• Integration of addiction and other healthcare
• Accurate terminology

Kelly E. Dunn, PhD
Johns Hopkins University School of Medicine
• Opioid use disorder, treatment, and comorbidities
• Alcohol use disorder and treatment
• Tobacco use and cessation
• Incentive-based treatments
• Individual differences
• Healthcare systems

Ismene Petrakis, MD
Yale University School of Medicine
• Opioid use disorder
• Psychiatric comorbidity
• Neurobiology
• Alcohol
• Psychopharmacology

Martha J. Wunsch, MD, FAAP, DFASAM
Kaiser Permanente Northern California
• Women and substance-exposed newborns
• Adolescent substance use disorder
• Pharmacological treatments
• Opioid overdose and treatment
• Epidemiology
• Prescription drug abuse

Frank J. Vocci, PhD
Friends Research
• Medication development
• Medical consequences
• HIV, AIDS, hepatitis C
• Opioids
• Stimulants
• Tobacco

Debbie M. Cheng, ScD
Boston University School of Public Health
Biostatistics
Longitudinal data analyses
Design and analysis of clinical trials
HIV

Charles Maynard, PhD
University of Washington
Statistics
Clinical trials
Public health
Policy
Military
Epidemiology

Katie Witkiewitz, PhD
University of New Mexico
Statistical methods
Empirically supported treatments for addiction
Mechanisms of behavior change
Addictive behavior relapse
Mindfulness-based and group-based relapse prevention

Robert M. Anthenelli, MD
University of California, San Diego
Cigarette smoking
Alcohol
Neurobiology
Comorbidity
Stress
Sex differences

Gary Aston-Jones, PhD
Rutgers University and Rutgers Behavioral and Health Sciences
Reward behavior
Cognitive function
Neurobiology and neurophysiology
Neuroanatomy
Behavioral pharmacology
Animal models

Yatan Pal Singh Balhara, MD, DNB (Psychiatry), MNAMS, MSc
All India Institute of Medical Sciences, New Delhi, India
Mental health policy and services
Comorbidity
“Dual” diagnosis
Behavioral/process addictions (Internet, gambling)
• eHealth

**Robert L. Balster, PhD**
Virginia Commonwealth University
• Drug addictive potential assessment
• Medication development
• Tobacco regulatory science
• Training

**Kathleen T. Brady, MD, PhD**
Medical University Of South Carolina
• Addiction psychiatry
• Gender and substance use disorders
• Pharmacotherapy of substance use disorders
• Comorbidity
• PTSD and other anxiety disorders

**Karen L. Cropsey, PsyD**
University of Alabama at Birmingham
• Tobacco
• Criminal justice
• HIV
• Opioids
• Treatment adherence

**James L. Ferguson, DO, DFASAM**
Recovery Management Solutions
• Forensic toxicology
• Medical Review Officer

**David A. Fiellin, MD**
Yale University
• Treatment strategies
• Opioid use disorder medication treatment
• Office-based, primary care, emergency department, and HIV specialty settings

**Michael Fingerhood MD, FACP, FASAM, AAHIVS**
Johns Hopkins University
• Medical complications of addiction, including HIV and HCV
• Alcohol
• Older adults and substance use disorders
• Buprenorphine
• Withdrawal management
• Ethical issues
Catherine Friedman, MD
Brown University
• Education
• Child and adolescent psychiatry
• Dual diagnosis
• Parenting, pregnancy, and addictions
• Women, addictions, and other psychiatric disorders
• Opioid use and cooccurring disorders

John A. Fromson, MD
Harvard Medical School
• Physician and medical student health
• Professional development
• Patient safety
• Physician monitoring

Marc Galanter, MD, MPH, DFASAM
New York University
• Family therapy
• Pharmacological treatment strategies
• Twelve-Step

Marc N. Gourevitch, MD, MPH, DFASAM
New York University School of Medicine
• Health service utilization and delivery systems
• Epidemiology and population health, including underserved populations
• Pharmacological treatments
• Primary care and public sector initiatives
• Translation from research to clinical application

Nady El Guebaly, MD, DPsych, DFASAM
University of Calgary
• Alcohol
• Gambling
• Substance use disorder education and training
• Comorbid substance use disorders
• Treatment programs

Kyle Kampman, MD, DFASAM
University of Pennsylvania
• Alcohol
• Cocaine
• Opioids
• Withdrawal syndrome
• Pharmacological treatments
• Psychotherapy
Jag Khalsa, MS, PhD
Formerly, Chief, Medical Consequences of Drug Abuse and Infections Branch, National Institute on Drug Abuse
Currently, Special Volunteer at NIDA/NIH
- Clinical research on medical and health consequences of drug use
- Comorbid viral infection (HIV, HCV)
- Drug development
- Cannabis/Medicinal cannabis

Barbara J. Mason, PhD
The Scripps Research Institute
- Medication development for protracted abstinence and relapse prevention
- Alcohol, cannabis and cigarettes
- Proof-of-concept early-phase human laboratory studies
- Double-blind, placebo-controlled clinical efficacy studies

Jane C. Maxwell, PhD
University of Texas Austin
- Epidemiology and patterns of use and emergence of drug trends
- Methamphetamine
- Black tar heroin
- Synthetic and new psychoactive drugs
- Methadone mortality
- Use of multiple data sources to identify new drug trends

Mark Potenza, MD, PhD
Yale University
- Neurobiology
- Addictions
- Impulse control
- Gambling

Gary M. Reisfield, M.D.
University of Florida College of Medicine
- Cannabis and other drugs
- Pharmacological treatment prescribers/pharmacy
- Drug monitoring programs
- Drug screening
- Pain
- Toxicology

Perry F. Renshaw, MD, PhD
University of Utah
- Imaging
- Neurochemistry
• Mood disorders
• Natural products as treatment strategies

Richard K. Ries, MD, DFASAM
University of Washington
• Suicide
• Medication management –Psychiatric and/or Addiction
• Mental healthcare
• Psychiatry
• 12 Step, other “self help” recovery

David E. Smith, MD, DFASAM
University of California at San Francisco
• Adolescent addiction
• Cannabis
• Toxicology
• Psychedelic misuse

Jon E. Sprague, PhD
Ohio Northern University
• Amphetamines
• Drug design
• Pharmacokinetics
• Bath salts
• MDMA
• Pharmacogenetics

Eric Strain, MD
Johns Hopkins School of Medicine
• Opioids
• Cannabis
• Alcohol
• Harm reduction and psychosocial factors
• Medication treatment
• Psychiatric comorbidity

Mishka Terplan, MD, MPH, FACOG, DFASAM
Virginia Commonwealth University
• Obstetrics and gynecology
• Harm reduction
• Public health
• Health disparities and stigma
• Gender and addiction

Nassima Ait-Daoud Tiouririne, MD
University of Virginia
• Medication development
• Biological and psychosocial factors
• Transcranial magnetic stimulation
• Depression and Psychiatry services

Michael F. Weaver, MD, DFASAM
The University of Texas Health Science Center at Houston
• Opioids
• Alcohol
• Opioid agonist therapy (buprenorphine, methadone)
• Prescription medication misuse
• Alcohol withdrawal
• Ethics

Joseph Westermeyer, MD, PhD, DFASAM
Minneapolis VAMC
• Psychiatric epidemiology
• Psychopathology across cultures
• Treatment outcome
• Trajectory of addiction with and without treatment
• Public health aspects (prevention, early intervention, social interventions, economic consequences)
• High-risk subgroups, comorbidities

George E. Woody, MD, DFASAM
University of Pennsylvania
• Substance use disorder treatment outcomes
• “Dual” diagnosis
• HIV risk reduction

Li-Tzy Wu, ScD, RN, MA
School of Medicine, Duke University Medical Center
• Opioids, Cannabis, Alcohol, Tobacco, Hallucinogens, Stimulants
• Pain, Medical Comorbidity
• Clinical trials
• Screening and brief intervention
• Health and pharmacy services research and healthcare integration
• Psychometric analysis and research design/methods
• Epidemiology

Nickolas D. Zaller, PhD
University of Arkansas for Medical Sciences
• Criminal justice
• Infectious diseases and HIV risk
• Opioids
• Injection drug use
• Harm reduction